Hosted on MSN25d
Genentech’s Itovebi combo hits overall survival endpoint in HER2- breast cancer
Genentech Therapeutics’s Phase III trial of Itovebi in patients with certain types of metastatic breast cancer has met the gold standard oncology endpoint of overall survival (OS) while also ...
Business Wire26d
Genentech’s Itovebi Demonstrated Statistically Significant and Clinically Meaningful Overall Survival Benefit in a Certain Type of HR-Positive Advanced Breast Cancer
You may also report side effects to Genentech at (877) 436-3683. Before you take Itovebi, tell your healthcare provider about all of your medical conditions, including if you: have a history of ...
Business Insider26d
Genentech announces INAVO120 study met key secondary endpoint
Genentech, a member of Roche (RHHBY), announced topline results from the overall survival analysis of the Phase III INAVO120 study investigating Itovebi in combination with palbociclib and ...
Cure Today24d
Itovebi-Based Treatment Has OS Benefit in PIK3CA+ HR+/HER2– Breast Cancer
Itovebi-based regimen significantly improved OS and PFS in PIK3CA-mutated, HR-positive, HER2-negative breast cancer patients. The FDA approved the Itovebi-based combination in October 2024 for ...
FiercePharma26d
Roche's breast cancer entrant Itovebi bolsters clinical profile with overall survival win
Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in combination with two established medicines, new survival data from ...